Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
Maya R Chilbert,1,2 Dylan VanDuyn,3 Sara Salah,1 Collin M Clark,1,2 Qing Ma1 1Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA; 2Department of Pharmacy, Buffalo General Medical Center, Buffalo, NY, USA; 3Department of Pharmacy,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/combination-therapy-of-ezetimibe-and-rosuvastatin-for-dyslipidemia-cur-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1811323120350396416 |
|---|---|
| author | Chilbert MR VanDuyn D Salah S Clark CM Ma Q |
| author_facet | Chilbert MR VanDuyn D Salah S Clark CM Ma Q |
| author_sort | Chilbert MR |
| collection | DOAJ |
| description | Maya R Chilbert,1,2 Dylan VanDuyn,3 Sara Salah,1 Collin M Clark,1,2 Qing Ma1 1Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA; 2Department of Pharmacy, Buffalo General Medical Center, Buffalo, NY, USA; 3Department of Pharmacy, Buffalo Veterans Affairs Medical Center, Buffalo, NY, USACorrespondence: Maya R Chilbert, Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 202 Pharmacy Building, Buffalo, NY, USA, Tel +1 716 829-5172, Fax +1 716-829-6093, Email mayahols@buffalo.eduAbstract: Cardiovascular disease is one of the leading causes of death around the world with various efforts being made to reduce risk in patients through preventive measures. One major method for prevention has been managing cholesterol, particularly low-density lipoprotein to decrease atherosclerotic plaque burden, potentially decreasing future cardiac complications. Statins have been the gold standard therapy for hypercholesterolemia treatment due to their ease of dosing, limited drug interactions, and favorable safety profile. Unfortunately, statin therapy alone is not always effective enough to adequately control a patient’s elevated lipid levels and combination therapy may be warranted. Ezetimibe is commonly added to regimens to help augment cholesterol lowering by inhibiting the absorption of cholesterol. The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We aimed to identify potential beneficial effects of ezetimibe by comparing its use in combination with high-intensity rosuvastatin compared to a statin therapy alone or in combination with moderate intensity simvastatin through a literature review. The current evidence indicated that combination therapy outperformed statin monotherapy in reduction of low-density lipoprotein cholesterol and patients were more likely to achieve their target low-density lipoprotein cholesterol goal level. This suggests rosuvastatin/ezetimibe combination holds a potential place in therapy for patients requiring a more aggressive reduction in cholesterol to help prevent atherosclerotic disease.Keywords: hypercholesterolemia, hyperlipidemia, cardiac events, lipid biomarkers, atherosclerosis |
| first_indexed | 2024-04-13T13:49:29Z |
| format | Article |
| id | doaj.art-e9dc165af3384ce48c009eab4581e529 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T13:49:29Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-e9dc165af3384ce48c009eab4581e5292022-12-22T02:44:24ZengDove Medical PressDrug Design, Development and Therapy1177-88812022-07-01Volume 162177218676426Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current InsightsChilbert MRVanDuyn DSalah SClark CMMa QMaya R Chilbert,1,2 Dylan VanDuyn,3 Sara Salah,1 Collin M Clark,1,2 Qing Ma1 1Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA; 2Department of Pharmacy, Buffalo General Medical Center, Buffalo, NY, USA; 3Department of Pharmacy, Buffalo Veterans Affairs Medical Center, Buffalo, NY, USACorrespondence: Maya R Chilbert, Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 202 Pharmacy Building, Buffalo, NY, USA, Tel +1 716 829-5172, Fax +1 716-829-6093, Email mayahols@buffalo.eduAbstract: Cardiovascular disease is one of the leading causes of death around the world with various efforts being made to reduce risk in patients through preventive measures. One major method for prevention has been managing cholesterol, particularly low-density lipoprotein to decrease atherosclerotic plaque burden, potentially decreasing future cardiac complications. Statins have been the gold standard therapy for hypercholesterolemia treatment due to their ease of dosing, limited drug interactions, and favorable safety profile. Unfortunately, statin therapy alone is not always effective enough to adequately control a patient’s elevated lipid levels and combination therapy may be warranted. Ezetimibe is commonly added to regimens to help augment cholesterol lowering by inhibiting the absorption of cholesterol. The recent approval of a combination tablet of high-intensity rosuvastatin and ezetimibe has introduced a potentially more beneficial option for cholesterol management in addition to the only available combination of moderate intensity simvastatin and ezetimibe. We aimed to identify potential beneficial effects of ezetimibe by comparing its use in combination with high-intensity rosuvastatin compared to a statin therapy alone or in combination with moderate intensity simvastatin through a literature review. The current evidence indicated that combination therapy outperformed statin monotherapy in reduction of low-density lipoprotein cholesterol and patients were more likely to achieve their target low-density lipoprotein cholesterol goal level. This suggests rosuvastatin/ezetimibe combination holds a potential place in therapy for patients requiring a more aggressive reduction in cholesterol to help prevent atherosclerotic disease.Keywords: hypercholesterolemia, hyperlipidemia, cardiac events, lipid biomarkers, atherosclerosishttps://www.dovepress.com/combination-therapy-of-ezetimibe-and-rosuvastatin-for-dyslipidemia-cur-peer-reviewed-fulltext-article-DDDThypercholesterolemiahyperlipidemiacardiac eventslipid biomarkersatherosclerosis |
| spellingShingle | Chilbert MR VanDuyn D Salah S Clark CM Ma Q Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights Drug Design, Development and Therapy hypercholesterolemia hyperlipidemia cardiac events lipid biomarkers atherosclerosis |
| title | Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights |
| title_full | Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights |
| title_fullStr | Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights |
| title_full_unstemmed | Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights |
| title_short | Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights |
| title_sort | combination therapy of ezetimibe and rosuvastatin for dyslipidemia current insights |
| topic | hypercholesterolemia hyperlipidemia cardiac events lipid biomarkers atherosclerosis |
| url | https://www.dovepress.com/combination-therapy-of-ezetimibe-and-rosuvastatin-for-dyslipidemia-cur-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT chilbertmr combinationtherapyofezetimibeandrosuvastatinfordyslipidemiacurrentinsights AT vanduynd combinationtherapyofezetimibeandrosuvastatinfordyslipidemiacurrentinsights AT salahs combinationtherapyofezetimibeandrosuvastatinfordyslipidemiacurrentinsights AT clarkcm combinationtherapyofezetimibeandrosuvastatinfordyslipidemiacurrentinsights AT maq combinationtherapyofezetimibeandrosuvastatinfordyslipidemiacurrentinsights |